US government buys Danish smallpox vaccine  

US Department of Health and Human Services has placed a multi-million order with Copenhagen-based Bavarian Nordic A/S

The US Department of Health and Human Services (HHS) has announced that Copenhagen-based Bavarian Nordic A/S has been awarded a three-year contract with the US National Institute of Allergy and Infectious Diseases (NIAID) to develop Bavarian Nordic’s proprietary MVA-BN safe smallpox vaccine. A total of two contracts have been awarded under the US government’s funding programme resulting in a total funding of USD 20 million during the first twelve months. The contract requires Bavarian Nordic to develop a plan for large-scale manufacture of MVA-BN to demonstrate how it could deliver up to 30 million doses to the federal government.


Bavarian Nordic has been developing MVA-BN as a safe smallpox vaccine for the last three years and has already produced a comprehensive package of pre-clinical and clinical data that meets several of the objectives outlined in the US contract. Bavarian Nordic is the only company to have already completed small animal studies and a Phase I clinical study in healthy volunteers, demonstrating the excellent safety and immunogenicity of MVA-BN. The collaboration with HHS is not expected to affect Bavarian Nordic’s expectations for 2003, which remain a turnover of DKK 500 million (USD 72 million) and a profit before tax of DKK 250 (USD 36 million). The news is widely reported in the Danish media today.

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×